Published in Nature on August 30, 2012
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer (2012) 4.97
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (2013) 4.88
Mitochondria and cancer. Nat Rev Cancer (2012) 4.81
Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov (2013) 4.72
A vaccine targeting mutant IDH1 induces antitumour immunity. Nature (2014) 3.90
How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature (2012) 3.77
Cancer cell metabolism: one hallmark, many faces. Cancer Discov (2012) 3.03
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature (2014) 2.77
DNA methylation dynamics in health and disease. Nat Struct Mol Biol (2013) 2.58
Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol (2014) 2.36
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell (2013) 2.33
The Emerging Hallmarks of Cancer Metabolism. Cell Metab (2016) 2.32
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev (2013) 2.31
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med (2013) 2.27
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev (2013) 2.12
D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev (2012) 2.10
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. Cancer Cell (2016) 2.08
Induction of sarcomas by mutant IDH2. Genes Dev (2013) 2.02
Stem cell metabolism in tissue development and aging. Development (2013) 2.01
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. ACS Med Chem Lett (2012) 2.00
Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell (2014) 1.99
The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem (2012) 1.79
Oncometabolites: linking altered metabolism with cancer. J Clin Invest (2013) 1.78
Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. Cell Stem Cell (2015) 1.71
Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med (2013) 1.71
From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell (2014) 1.70
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol (2012) 1.68
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell (2015) 1.58
Mitochondrial dysfunction in cancer. Front Oncol (2013) 1.57
Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol (2013) 1.54
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. Oncologist (2016) 1.51
Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. J Pathol (2016) 1.45
Understanding metabolic regulation and its influence on cell physiology. Mol Cell (2013) 1.43
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood (2013) 1.37
IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res (2012) 1.36
What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol (2013) 1.36
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res (2014) 1.33
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood (2013) 1.33
Notch signaling: switching an oncogene to a tumor suppressor. Blood (2014) 1.32
IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep (2013) 1.32
Breathing-in epigenetic change with vitamin C. EMBO Rep (2013) 1.29
Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia (2014) 1.28
Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet (2014) 1.24
bHLH-PAS proteins in cancer. Nat Rev Cancer (2013) 1.23
Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med (2013) 1.23
Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell (2014) 1.23
5-hydroxymethylcytosine and its potential roles in development and cancer. Epigenetics Chromatin (2013) 1.20
IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res (2014) 1.19
TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev (2015) 1.18
Genomic insights into cancer-associated aberrant CpG island hypermethylation. Brief Funct Genomics (2013) 1.11
Interactions between epigenetics and metabolism in cancers. Front Oncol (2012) 1.11
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells. J Clin Invest (2012) 1.10
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res (2014) 1.09
Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. Stem Cells Transl Med (2013) 1.09
Nutrient-sensing pathways and metabolic regulation in stem cells. J Cell Biol (2013) 1.08
Releasing the block: setting differentiation free with mutant IDH inhibitors. Cancer Cell (2013) 1.07
Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). J Biol Chem (2012) 1.06
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res (2013) 1.04
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs (2014) 1.04
DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proc Natl Acad Sci U S A (2014) 1.02
Isocitrate dehydrogenase mutations in leukemia. J Clin Invest (2013) 1.01
Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia (2013) 1.00
New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma. Int J Med Sci (2015) 1.00
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nat Chem Biol (2015) 0.99
Bisulfighter: accurate detection of methylated cytosines and differentially methylated regions. Nucleic Acids Res (2014) 0.98
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev (2014) 0.97
Differentiation therapy for IDH1/2 mutant malignancies. Cell Res (2013) 0.97
Metabolic regulation of stem cell function. J Intern Med (2014) 0.97
A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. Leukemia (2013) 0.96
Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol (2016) 0.96
A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. Cancer Discov (2014) 0.95
Targeting metabolism to induce cell death in cancer cells and cancer stem cells. Int J Cell Biol (2013) 0.94
Understanding the Intersections between Metabolism and Cancer Biology. Cell (2017) 0.94
Dissecting the role of aberrant DNA methylation in human leukaemia. Nat Commun (2015) 0.93
Molecular biology of gliomas: present and future challenges. Transl Med UniSa (2014) 0.92
Sum of the parts: mass spectrometry-based metabolomics. Biochemistry (2013) 0.92
Targeting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol (2015) 0.92
Metabolic mechanisms of epigenetic regulation. ACS Chem Biol (2013) 0.92
The evolution of genome-scale models of cancer metabolism. Front Physiol (2013) 0.92
Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther (2015) 0.90
Mutant IDH is sufficient to initiate enchondromatosis in mice. Proc Natl Acad Sci U S A (2015) 0.89
HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. J Clin Invest (2014) 0.88
Brain stem cells as the cell of origin in glioma. World J Stem Cells (2014) 0.88
R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell (2013) 0.85
Alterations of 5-hydroxymethylcytosine in human cancers. Cancers (Basel) (2013) 0.85
Manganese superoxide dismutase depletion in murine hematopoietic stem cells perturbs iron homeostasis, globin switching, and epigenetic control in erythrocyte precursor cells. Free Radic Biol Med (2012) 0.85
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. Oncotarget (2015) 0.84
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget (2015) 0.84
Targeting of two aspects of metabolism in breast cancer treatment. Cancer Biol Ther (2014) 0.83
From systems to structure: bridging networks and mechanism. Mol Cell (2013) 0.83
The epigenetic role of vitamin C in health and disease. Cell Mol Life Sci (2016) 0.83
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. Leukemia (2016) 0.82
Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice. Leukemia (2014) 0.82
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. Clin Cancer Res (2016) 0.82
The role of 5-hydroxymethylcytosine in human cancer. Cell Tissue Res (2014) 0.81
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. Mol Cancer Res (2016) 0.81
Glutamate and α-ketoglutarate: key players in glioma metabolism. Amino Acids (2016) 0.81
Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Rep (2015) 0.81
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
lumi: a pipeline for processing Illumina microarray. Bioinformatics (2008) 17.19
The UCSC Genome Browser database: update 2011. Nucleic Acids Res (2010) 16.24
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res (1999) 12.83
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science (2009) 10.78
Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics (2011) 9.79
Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res (2005) 8.69
Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med (2006) 7.62
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature (2011) 5.78
Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat Biotechnol (2008) 5.77
Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur J Immunol (2003) 5.73
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep (2011) 4.89
Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography-tandem mass spectrometry. J Chromatogr A (2006) 4.62
Hematopoietic stem cells expressing the myeloid lysozyme gene retain long-term, multilineage repopulation potential. Immunity (2003) 3.59
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell (2011) 3.12
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet (2012) 2.94
The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol (2010) 2.63
The OP9-DL1 system: generation of T-lymphocytes from embryonic or hematopoietic stem cells in vitro. Cold Spring Harb Protoc (2009) 1.66
Complex and context dependent regulation of hematopoiesis by TGF-beta superfamily signaling. Ann N Y Acad Sci (2009) 1.45
Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med (2010) 1.39
Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol (2011) 1.36
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia (2011) 1.35
Self-renewal related signaling in myeloid leukemia stem cells. Int J Hematol (2011) 1.17
Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects. Curr Opin Hematol (2008) 1.02
International network of cancer genome projects. Nature (2010) 20.35
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol (2010) 9.24
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell (2002) 9.10
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 7.73
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer (2006) 7.53
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature (2004) 7.21
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
LPS/TLR4 signal transduction pathway. Cytokine (2008) 6.60
An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol (2003) 6.46
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol (2012) 6.20
DNA methylation profiles in monozygotic and dizygotic twins. Nat Genet (2009) 5.99
Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res (2006) 5.99
Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science (2011) 5.87
The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol (2007) 5.83
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med (2010) 5.68
Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature (2006) 5.49
Specific ablation of the apoptotic functions of cytochrome C reveals a differential requirement for cytochrome C and Apaf-1 in apoptosis. Cell (2005) 5.37
Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature (2005) 5.37
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev (2008) 4.85
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov (2013) 4.72
Long-term survival with glioblastoma multiforme. Brain (2007) 4.51
A molecular roadmap of reprogramming somatic cells into iPS cells. Cell (2012) 4.41
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol (2009) 4.32
Lipocalin-2 resistance confers an advantage to Salmonella enterica serotype Typhimurium for growth and survival in the inflamed intestine. Cell Host Microbe (2009) 4.20
WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity (2003) 4.07
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 4.00
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol (2008) 3.91
Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2006) 3.85
Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A (2005) 3.83
Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. Genes Dev (2003) 3.79
FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med (2006) 3.78
Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer (2004) 3.76
Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature (2002) 3.74
Microarray-based DNA methylation profiling: technology and applications. Nucleic Acids Res (2006) 3.73
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science (2013) 3.72
Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med (2005) 3.70
Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med (2012) 3.67
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol (2009) 3.65
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell (2011) 3.61
Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Dev (2002) 3.55
Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol (2013) 3.55
methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol (2012) 3.44
DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A (2006) 3.41
CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol (2004) 3.36
Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol (2004) 3.33
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat Immunol (2010) 3.27
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Histological classification and molecular genetics of meningiomas. Lancet Neurol (2006) 3.19
Control of cell polarity and motility by the PtdIns(3,4,5)P3 phosphatase SHIP1. Nat Cell Biol (2006) 3.19
The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol (2003) 3.18
DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell (2005) 3.12
Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer (2007) 3.10
Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. Hepatology (2015) 3.10
A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell (2006) 3.10
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med (2004) 3.10
Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med (2008) 3.10
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol (2003) 3.07